Want to join the conversation?
$BIIB expects its full year 2016 revenue to be approx. $11.1Bil to $11.3Bil, which is higher than the 2015 revenue of $10.8Bil. GAAP diluted EPS is expected to be between $16.85 and $17.15. CEO George Scangos said that the company is excited about the potential new launches of BENEPALI, ZINBRYTATM, and an infliximab biosimilar in 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?